Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 16/20 | 0.69 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6982673 | 0.84 | BRS3 (0.67) | BRS3 | |
| SCHEMBL1695149 | 0.69 | BRS3 (0.52) | BRS3 | |
| SCHEMBL3514348 | 0.65 | BRS3 (0.66) | BRS3 | |
| SCHEMBL6983857 | 0.64 | BRS3 (0.59) | BRS3 | |
| SCHEMBL3522189 | 0.63 | BRS3 (0.57) | BRS3 | |
| SCHEMBL6990015 | 0.63 | BRS3 (0.51) | BRS3 | |
| SCHEMBL6983410 | 0.63 | BRS3 (0.67) | BRS3 | |
| SCHEMBL3522632 | 0.62 | BRS3 (0.57) | BRS3 | |
| SCHEMBL3519666 | 0.62 | BRS3 (0.55) | BRS3 | |
| SCHEMBL6989344 | 0.61 | BRS3 (0.52) | BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| WO-2008051405-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | BRS3 1/4885PRKAB2 2713/4885PRKAG1 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.